Impact of Subsequent Immune Checkpoint Inhibitor Treatment on Overall Survival With Avelumab vs Docetaxel in Platinum-Treated Advanced NSCLC: Post Hoc Analyses From the Phase 3 JAVELIN Lung 200 Trial
Avelumab is a human anti–programmed cell death 1 ligand 1 (PD-L1) IgG1 antibody that has shown durable antitumor activity and an acceptable safety profile in patients with a range of tumor types [1–7].